Charles Kandalaft, MD
Psychiatry · Valhalla, NYNPI 1467499798
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 29.7% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$801
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$697
- Lundbeck LLC$515
- Otsuka America Pharmaceutical, Inc.$305
- Axsome Therapeutics, Inc.$239
- plus $546 from 9 others
What the payments were for
- Food & beverage$4,411100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $801 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $697 |
| Lundbeck LLC | 23 | $515 |
| Otsuka America Pharmaceutical, Inc. | 14 | $305 |
| Axsome Therapeutics, Inc. | 8 | $239 |
| Bausch Health US, LLC | 6 | $134 |
| Johnson & Johnson | 5 | $130 |
| Avanir Pharmaceuticals, Inc. | 4 | $77 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Shire North American Group Inc | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $15 |
How this compares
$4,418 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 25 | $20,375 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $8,550 |
| Bupropion XlBupropion Hcl | 231 | $5,559 |
| Clonazepam | 159 | $1,497 |
| Duloxetine Hcl | 37 | $1,342 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 35 | $1,314 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 94 | $1,152 |
| Escitalopram Oxalate | 99 | $1,111 |
| Fluoxetine Hcl | 78 | $1,098 |
| Gabapentin | 62 | $989 |
| Aripiprazole | 46 | $977 |
| Nortriptyline Hcl | 25 | $837 |
| Trazodone Hcl | 80 | $726 |
| Lamotrigine | 47 | $719 |
| Zolpidem Tartrate | 99 | $634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $801 | $28,92539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Valhalla
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.